Wire · operational-macro
Enliven Therapeutics Stock Losses Widen As Phase 3 Trial Plan Gets FDA Alignment
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 November 2026 · Fusion42 review
Enliven Therapeutics reported widening losses in Q3 2026 alongside FDA alignment on their ENABLE 2 Phase 3 trial design for relcobatinib, with cash expected to fund operations into 2030, reducing near-term funding risk as they focus on trial execution.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 5 Nov 2026 and 8 Nov 2026.
◆ ◆ The Wire takeaway
Enliven's FDA alignment lowers regulatory uncertainty but your main challenge is delivering trial starts and quality data on time to unlock value before losses deepen. Cash into 2030 buys you runway to focus on execution without urgent fundraising.
◆ Coverage
2 sources · first reported 5 Nov 2026 · latest 8 Nov 2026
◆ Related on Wire
◆ Topics